(3 years, 1 month ago)
Commons ChamberAny private company or public organisation worth its salt will have procurement policies in place that ensure it purchases materials that provide value for money and are fit to do the job. Those working in procurement teams will be expected to maintain high standards of propriety and ethics. Contracts to supply will be based on a mature purchasing system that has been developed over years, to ensure that both the purchaser and the supplier are satisfied with the deal, which means paying a fair price for suitable goods. That is a basic, standard guideline. Any junior procurement officer would understand that from day one.
Yet the procurement process that is within the full control of the UK Government, controller of all UK citizens’ tax, appears to have embarked on a poorly orchestrated spending spree, with many contracts being handed out in what can only be described as dubious fashion.
Recently, the Government quietly published the details of 40 PPE contracts awarded a year ago during the first wave of the pandemic. The value of those contracts was an eye-watering £4.2 billion. I accept the figures will be large when the Government hand out contracts, so what is required is transparency and the utmost integrity. I am sure we all remember our maths teacher setting problems for us and saying, “I don’t just want the answer. I want to see your workings.” The same principle applies.
It is interesting that 365 Healthcare, a trading division of Bunzl, was handed a £151 million PPE deal on 1 April 2020 without explaining why it won the contract or what was better about its bid compared with the competition. That is not good enough, especially when, as the Good Law Project revealed, a Conservative peer had lobbied for PPE contracts on behalf of Bunzl while still acting as an adviser to DHSC. Globus Shetland landed a £14 million deal in April 2020 to provide eye protection and respirators. The firm had previously donated £375,000 to the Conservative party.
The UK Government should be held up to the highest scrutiny, and they should govern in such a way that they have nothing to fear. Who created the VIP list? What were the criteria, and what was the motive behind creating such a list? Emails revealed in a hearing during the legal challenge by the Good Law Project to the direct award of PPE contracts show civil servants raising the alarm that they were drowning in VIP requests from political connections that did not have the correct certification or could not pass due diligence. One email showed a civil servant warning that, when VIPs jump to the front of the queue, there is a knock-on effect on the remaining offers of help. Why were these civil servants ignored? Who within the UK Government thought they knew better? This is not scaremongering; the facts exist if we are prepared to look for them.
In February, the Prime Minister falsely claimed that details of all PPE contracts awarded by the Government had been published and were on the record. A few weeks later, a Cabinet Office Minister doubled down on the Prime Minister’s statement, claiming that he spoke accurately. Well, they were both wrong. This leads to a lack of confidence in the Government over the pandemic. It undermines the sacrifice that millions have made and it mocks the financial hardship that so many citizens throughout the UK are facing during the pandemic. A deadly pandemic should not be an opportunity for the UK Government to line the pockets of their cronies and business acquaintances, and yet the more we scrutinise the PPE contracts awarded by the UK Government, the more the questions arise. Enormous amounts of public money have been handled without any advertising or competitive tendering process.
This simply is not good enough, and we have to understand why these mistakes have been made. To protect taxpayers’ money and prevent further PPE procurement failures, we need answers. We need a public inquiry that is free from UK Government interference. Only with good procurement practice, which means learning from mistakes, can we safeguard the lives of the public and our highly valued healthcare workers, and that comes from scrutiny of and transparency from the UK Government.
(3 years, 2 months ago)
Commons ChamberI would first like to thank the hon. Member for the part he played in campaigning for this life-saving change to organ donation and bringing about the increase that I mentioned earlier. The current services are now running at pre-covid levels and NHS Blood and Transplant is working with the wider healthcare system to enable as many transplants as possible. The new Organ Donation and Transplantation 2030: Meeting the Need strategy, which was launched last Tuesday, sets out the steps we are taking to increase organ availability further.
I have discussed these concerns with the hon. Member and with the co-chairs of the all-party parliamentary group on medical cannabis under prescription, and he knows that I sympathise deeply with the parents of these children and with the patients and their families, many of whom I have met. They are dealing courageously with conditions that are difficult to treat. My immediate priority was to resolve the supply of Bedrocan oil from the Netherlands. I have further meetings planned to make progress on other issues in this incredibly complex situation.
I welcome today’s letter from the Minister detailing the extension of the arrangements for the provision of Bedrocan, and I am pleased that we are working towards the manufacture of Bedrocan oils in the UK. I have two issues today. The first is that patients still need to pay for their medicines. If the numbers are so small and this is such a niche product, surely it could be provided free on the NHS. Secondly, I have been told that research is ongoing regarding the wider possibilities for medical cannabis, but despite being promised an update a month ago, I am still waiting for one from the Medicines and Healthcare Products Regulatory Agency on clinical trials and the licence application. Could that please be forthcoming?
As the hon. Gentleman knows, I have met Dr June Raine from the MHRA and subsequently met further specialist clinicians in this area to discuss progress with the research and evidence on supporting prescribing on the NHS. Establishing clinical trials is vital, with the support of the National Institute for Health Research, to make sure that we are making the right decisions on routine funding. From 1 April, we have introduced a national patient registry to record data and monitor patient outcomes in England, with a view to it being rolled out across Scotland and the other devolved Administrations later this year; this covers both licensed and unlicensed cannabis-based medicines on the NHS, with a view to including private patients in due course. As he knows, I am very focused on making sure we get the right solutions for families, but at the heart of this matter always has to lie the safety of what we prescribe.
(4 years, 5 months ago)
Commons ChamberUrgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Yes, absolutely, and if my right hon. Friend could bring the individual concerns to my attention, I would be very happy to look into them.
My constituents of Inverclyde are expecting 80 visits from cruise ships during the sailing season, which starts in April, including from the Regal Princess, which is due in on 10 May. What plans do the UK Government have in place should there be an outbreak on a cruise ship in UK waters?
We are, of course, working with Public Health England on making sure that we have the right answers should this happen. Looking into what happens on cruise ships and what advice will be given with respect to people going on future cruises is a critical piece of work that we are undertaking.